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Abstract
Background: We evaluated the effect of insulin stimulation and dietary changes on myocardial, skeletal muscle
and brain [18F]-fluorodeoxyglucose (FDG) kinetics and uptake in vivo in intact mice.
Methods: Mice were anesthetized with isoflurane and imaged under different conditions: non-fasted (n = 7;
“controls“), non-fasted with insulin (2 IU/kg body weight) injected subcutaneously immediately prior to FDG (n = 6),
fasted (n = 5), and fasted with insulin injection (n = 5). A 60-min small-animal PET with serial blood sampling and
kinetic modeling was performed.
Results: We found comparable FDG standardized uptake values (SUVs) in myocardium in the non-fasted controls and
non-fasted-insulin injected group (SUV 45-60 min, 9.58 ± 1.62 vs. 9.98 ± 2.44; p = 0.74), a lower myocardial SUV was
noted in the fasted group (3.48 ± 1.73; p < 0.001). In contrast, the FDG uptake rate constant (Ki) for myocardium
increased significantly by 47% in non-fasted mice by insulin (13.4 ± 3.9 ml/min/100 g vs. 19.8 ± 3.3 ml/min/100 g; p =
0.030); in fasted mice, a lower myocardial Ki as compared to controls was observed (3.3 ± 1.9 ml/min/100 g; p < 0.001).
Skeletal muscle SUVs and Ki values were increased by insulin independent of dietary state, whereas in the brain, those
parameters were not influenced by fasting or administration of insulin. Fasting led to a reduction in glucose metabolic
rate in the myocardium (19.41 ± 5.39 vs. 3.26 ± 1.97 mg/min/100 g; p < 0.001), the skeletal muscle (1.06 ± 0.34 vs.
0.34 ± 0.08 mg/min/100 g; p = 0.001) but not the brain (3.21 ± 0.53 vs. 2.85 ± 0.25 mg/min/100 g; p = 0.19).
Conclusions: Changes in organ SUVs, uptake rate constants and metabolic rates induced by fasting and insulin
administration as observed in intact mice by small-animal PET imaging are consistent with those observed in
isolated heart/muscle preparations and, more importantly, in vivo studies in larger animals and in humans. When
assessing the effect of insulin on the myocardial glucose metabolism of non-fasted mice, it is not sufficient to just
calculate the SUV - dynamic imaging with kinetic modeling is necessary.
Background
The development of high-spatial-resolution small-animal
PET has opened a new field for translational research.
With these dedicated devices, regional organ tissue radio-
tracer concentrations can be visualized and measured.
Moreover, radiotracer tissue kinetic models initially
established and validated in larger animals and in
humans for measurements of regional functional
processes can now be applied to small animals. It is thus
possible to study myocardial substrate metabolism and
its determinants in intact animals rather than in isolated
hearts. Importantly, because PET allows simultaneous
measurements of radiotracer uptake and tissue kinetics
in multiple organs such as skeletal muscle, brain, and
myocardium, system-wide response of individual organ
metabolic rates to physiological or pharmacological
stimuli can be evaluated.
The small organ size in these animals, together with
limitations in blood sampling, poses considerable metho-
dological challenges. Accordingly, only few investigations
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have attempted to measure glucose metabolic rates in the
myocardium, skeletal muscle, and brain in mice or rats
[1-6]; many of them addressed mainly methodological
aspects. Earlier studies from our laboratory have already
demonstrated the feasibility of determining the radiotra-
cer arterial input function and the tissue kinetics in myo-
cardium, skeletal muscle, and brain in intact mice [7-10].
The purpose of the current study was to determine, if
myocardial [18F]-fluorodeoxyglucose (FDG) kinetics in
mice in a non-fasting condition or a fasting condition dif-
fer after injection of insulin and furthermore assess the
effect on FDG kinetics in the muscle and brain. Knowl-
edge of the extent of these changes will assist in planning
future experiments for assessing glucose metabolism to
help decide if kinetic modeling is necessary or which
metabolic state would be the most suitable to answer the
scientific question.
Methods
Study design
Twenty-three male C57BL/6 mice (age 12-24 weeks,
Charles River Laboratories Inc., Wilmington, MA, USA)
were assigned to four study groups (Table 1). Non-
fasted, fed ad libitum mice served as “control group”
(n = 7). In the second group, defined as “non-fasted
insulin” (n = 6), mice were injected subcutaneously with
short-acting insulin (2 IU/kg body weight; Novolin R
Human, Novo Nordisk Pharmaceutical Industries Inc.,
Clayton, NC, USA) 30-60 s prior to the intravenous
(i.v.) FDG administration. In the third group, defined as
“fasted, no insulin” (n = 5), mice were kept without
chow overnight to assess the effects of fasting. Finally, in
the fourth group, defined as “fasted, insulin” (n = 5), the
effect of acute insulin administration immediately prior
to the i.v. FDG on the FDG tissue kinetics was
examined.
All animals were kept on a normal 12-h day/night
cycle, had free access to water and were studied between
8 and 10 am to minimize circadian variations of sub-
strate metabolism. Standard chow (Teklad S-2335
Mouse Breeder Diet 7904, Harlan Teklad Animal Diets
& Bedding, Indianapolis, IN, USA; 17.0% protein, 11.0%
fat, and <3.5% fiber) was used. The study was approved
by the UCLA Animal Research Committee and per-
formed in accordance with NIH Guidelines for the Care
and Use of Laboratory Animals.
Animal preparation and imaging procedure
Mice were anesthetized by inhalation of 2% isoflurane
(Isoflo, Abbott Laboratories, North Chicago, IL, USA) in
100% oxygen in an induction box heated to 36°C. The
animals were placed on a heated PET-CT animal holder,
which provided anaesthesia through a nose cone [11]. A
29 G needle, attached to a 5-7 cm long polyethylene
catheter (PE 20; Intramedic, Clay Adams, Sparks, MD,
USA) was inserted into the proximal tail vein.
A 60-minute microPET list mode data acquisition was
started 2 - 5 seconds prior to an i.v. FDG bolus (18.1 ±
5.5 MBq in 30 μl). Five to 13 serial venous blood sam-
ples (warmed tail tip, 4-17 μl/sample) were collected
during the study from the tail tip for determination of
plasma FDG concentrations. Plasma glucose levels were
measured before and following insulin administration
(5-13 samples) using tail vein blood samples (~0.3 μl
each), with glucose test strips (Therasense® Freestyle®,
Therasense Inc., Alameda, CA, USA). Blood loss due to
blood sampling averaged 134.4 ± 40.0 μl, which was less
than 10% of the total blood volume of a mouse.
A microCT study (microCAT™ II, Siemens Preclinical
Solutions, Knoxville, TN, USA) was performed upon
completion of the PET study.
Image reconstruction and analysis
Small-animal PET was performed on a microPET® Focus
220 system (Siemens Preclinical Solutions). Starting at the
time of injection, the acquired list mode data were binned
into 30 image frames (15 × 0.5, 1 × 2, 1 × 4, 1 × 6, 1 × 15,
3 × 30, 1 × 60, 1 × 120, 3 × 180, 3 × 900 s). Reconstruction
incorporated a filtered backprojection algorithm with a
ramp filter and a cutoff frequency of 0.5 of the Nyquist fre-
quency to obtain an image pixel size of 0.4 × 0.4 × 0.8 mm
and an inter-plane spacing and slice thickness of 0.8 mm
in a 128 × 128 matrix. The image reconstruction software
provided for correction of radioactivity decay, random
coincidences, dead-time losses, and photon attenuation
(microPET® Manager v. 2.1.5.0; Siemens Preclinical Solu-
tions). Photon attenuation was corrected for by CT-derived
attenuation maps as described previously [12].
Quantitative image analysis
The software AMIDE [13] was used for image display and
volume of interest (VOI) analysis. A large cylindrical VOI
was assigned to the whole body of the mouse (109 cm3),
an ellipsoidal VOI to the brain (57.5 mm3) and four small,
same-size box VOIs (2.2 mm3 each) to the myocardium as
visualized on the late phase PET images. Another small
box shaped VOI (1.4 mm3) was assigned to a proximal
foreleg muscle on the coregistered CT images. Finally, a
cylindrical VOI (2.6 mm3) was placed into the left ventri-
cle (LV) blood pool on the radiotracer first pass (early
time frame) images.
Table 1 Characteristics of the four study groups
Group no. n Metabolic condition Weight (g)
1 7 Non-fasted, no insulin; “controls” 28.9 ± 4.7
2 6 Non-fasted, insulin 28.3 ± 3.6
3 5 Fasted, no insulin 29.1 ± 4.1
4 5 Fasted, insulin 29.4 ± 5.1
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Standardized uptake value (SUV) was calculated to
normalize the radiotracer tissue concentrations to the
injected dose and body weight according to the follow-
ing equation:
SUV =
mean tissue counts (count/milliliter/second)
injected dose (count/second)/body weight (gram)
(1)
The injected dose was estimated from the total counts
in the whole-body VOI assigned to the last image frame
as described previously [14]. The tissue activity concen-
trations were obtained from the VOIs on the last 900-s
image.
Radiotracer concentrations in myocardium were deter-
mined from the average counts in the four myocardial
VOIs. For measurement of the radiotracer input func-
tion, blood sample radioactivity concentrations were
determined in a high-energy g counter (Packard Cobra
II Auto Gamma, Perkin Elmer Inc., Wellesley, MA,
USA). The input function was determined by a pre-
viously published method that uses the early portion
(t ≤ 1 min) of LV time-activity curve derived from
image data, adjusted for delay, dispersion, and partial-
volume effects, and two arterialized blood samples taken
from the tail vein at about 45 and 60 min p.i. [8].
Time-dependent changes in the distribution of FDG
concentrations in whole blood and plasma were cor-
rected for by the following equation established pre-
viously by our group [15]:
cf = 0.386 · e−0.191·t + 1.165 (2)
where cf is the correction factor, t the time in minutes
after the FDG injection.
From the input function and the image-derived organ
FDG concentrations, the FDG uptake rate constant (Ki)
was estimated with the Gjedde-Patlak graphical analysis
[16,17]
CT(T)
CP (T)
= Ki
∫ T
0 Cp(t)dt
Cp(T)
+ INT (3)
whereas CT(T) and Cp(T) are the tissue and plasma
radioactivity concentrations at each sample time point T
(4 to 22 min; [9]), t is the integration variable, and INT
is the y-intercept of the graphical plot. All calculations
were performed with the internet-based software
“Kinetic Imaging System” [18]. Linearity of the graphical
plot was confirmed visually. For all assessed organs a
specific density of 1.00 g/ml was assumed.
Glucose metabolic rates (MRgluc) were estimated by
MRgluc = (Ki × Cgluc)/LC, where Cgluc is the glucose con-
centration in plasma and LC the lumped constant. A
value of 1 was assumed for the lumped constant.
Because of marked changes in plasma glucose levels
after insulin administration, glucose metabolic rates
were estimated only for the groups without insulin
injection.
To evaluate group differences in the FDG plasma
clearance, the input function was normalized for body
weight and injected dose in the same way as the tissue
data and expressed as SUV. Since the time points of
blood sampling and plasma glucose measurements var-
ied slightly from mouse to mouse, interpolation was
applied for the inter-group analysis at predefined time
points.
Statistical analysis
Data are given with mean values and standard deviation.
Differences in SUVs, uptake rate constants, metabolic
rates, input functions, and plasma glucose levels in the
non-fasted control animals compared to the other ani-
mal groups were evaluated for statistical significance by
one-way ANOVA analysis. Intra-group differences in
plasma FDG and glucose levels were evaluated using the
Student’s t test. When comparing more than two groups
Bonferroni post-hoc corrections were applied. p values <
0.05 were considered to indicate statistical significance.
Results
Influence of fasting and insulin administration on plasma
glucose and [18F]-activity concentrations
Plasma glucose levels in the control group were signifi-
cantly higher as compared to the fasted group (137 ± 17
vs. 98 ± 14 mg/dl; p = 0.009). Plasma glucose levels pro-
gressively increased in control animals within 60 min
(166 ± 25 mg/dl; p = 0.003), but remained relatively
constant in fasted animals (Figure 1). In both insulin
groups, plasma glucose levels steeply declined; by 30
min, they had decreased to 63.0 ± 4.8% and 70.8 ± 7.3%
of the initial values.
In fasted animals, plasma [18F]-activities declined less
rapidly during the microPET study as compared to non-
fasted controls (Figure 2). As early as 10 min p.i., [18F]-
activity concentrations were higher in fasted animals (p =
0.048), suggesting that circulating FDG remained avail-
able longer for uptake into tissue.
Insulin administration was associated with a faster
decline of [18F]-plasma activities especially in non-fasted
controls. Significantly lower values were noted already
after 15 min in the non-fasted insulin group and after
30 min in the fasted insulin group (Figure 2), consistent
with insulin-stimulated higher whole-body glucose and
FDG disposal rates.
FDG uptake, uptake rate constants, and glucose
utilization rates
Figure 3 depicts representative PET images of the study
groups. Compared to the non-fasted control group, SUV
in myocardium of fasted mice was significantly lower
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Figure 1 Plasma glucose levels in the four groups of mice. Insulin injection resulted in a rapid decline of plasma glucose levels. The
insulin injected groups were shifted by 0.3 min to reduce overlay of error bars. * p < 0.05 vs. non-fasted controls by ANOVA and after
Bonferroni correction.
Figure 2 Plasma FDG concentrations in the four groups of mice. In both insulin groups FDG cleared from plasma more rapidly than in the
groups without insulin injection. Y axis is in logarithmic scale. The insulin injected groups were shifted by 0.3 min to reduce overlay of error
bars. * p < 0.05 vs. controls by ANOVA and after Bonferroni correction.
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(3.48 ± 1.73 vs. 9.58 ± 2.44; p < 0.001, Table 2). In ske-
letal muscle, a trend for a lower SUV was observed
(0.40 ± 0.09 vs. 0.55 ± 0.11; p = 0.079). The brain SUV
was found to be higher in fasted compared to control
mice (2.87 ± 0.50 vs. 1.45 ± 0.42; p < 0.001). Interest-
ingly, myocardial SUV in non-fasted control mice did
not increase with insulin administration. Graphical ana-
lysis was applied in all mice to calculate tissue specific
Ki; correlation coefficients of least square fits averaged
R2 = 0.984 ± 0.007. Examples of Patlak plots of a non-
fasted and an insulin treated mouse are shown in
Figure 4.
In parallel to calculated SUVs, myocardial Ki values in
the fasted group were found to be significantly lower
(-75.5%) compared to non-fasted controls (Table 2; p <
0.001). Insulin administration produced a significant
increase in Ki values in both groups. In contrast to SUV,
insulin led to an increase in Ki in non-fasted animals,
on average 43.5% (p = 0.030) compared to controls. In
fasted mice, insulin produced myocardial Ki values,
which were more than 300% higher than without (20.0
± 12.7 vs. 3.3 ± 1.9; p < 0.001). Insulin stimulation led
to similar myocardial Ki values in fasted mice as in non-
fasted controls despite a significant difference in plasma
glucose levels before the PET study.
In skeletal muscle, concordant changes in Ki were
noted with the highest values after insulin administra-
tion (Table 2). Brain Ki values were not affected by insu-
lin or fasting.
Consistent with the Ki changes, MRgluc considerably
differed between the non-fasted and the fasted animals
in the insulin-sensitive organs (Table 2). Fasting was
associated with an 81% reduction in myocardial and a
68% reduction in skeletal muscle MRgluc when com-
pared to non-fasted controls.
Figure 3 Representative small-animal PET images. Myocardial uptake is very similar in control animals as compared to the insulin-injected
animals, but in the skeletal muscle, more FDG uptake can be noted after insulin injection. In fasted animals, myocardial FDG is markedly
diminished. Sagittal (top) and transverse (bottom) views of one mouse of each group obtained 45-60 min p.i.
Table 2 Organ standardized uptake values (SUV), FDG
uptake rate constants (Ki) and glucose metabolic rates
(MRgluc)
Myocardium Muscle Brain
SUV (45-60 min p.i.)
Non-fasted 9.5 ± 2.4 0.55 ± 0.11 1.45 ± 0.41
Non-fasted and insulin 9.98 ± 1.06 0.97 ± 0.29* 0.96 ± 0.11*
Fasted 3.48 ± 1.73* 0.40 ± 0.09 2.87 ± 0.50*
Fasted and insulin 9.35 ± 1.62 1.00 ± 0.24* 1.73 ± 0.41
Ki (ml/min/100 g)
Non-fasted 13.44 ± 3.93 0.73 ± 0.25 2.24 ± 0.53
Non-fasted and insulin 19.79 ± 3.34* 1.89 ± 0.86* 2.52 ± 0.58
Fasted 3.34 ± 1.92* 0.36 ± 0.11* 2.99 ± 0.39
Fasted and insulin 20.01 ± 12.70 2.04 ± 1.80* 3.56 ± 1.21
MRgluc (mg/min/100 g)
Non-fasted 19.41 ± 5.39 1.06 ± 0.34 3.21 ± 0.53
Fasted 3.26 ± 1.97* 0.34 ± 0.08* 2.85 ± 0.23
*p < 0.05 vs. non-fasted controls by ANOVA and after Bonferroni correction.
Kreissl et al. EJNMMI Research 2011, 1:8
http://www.ejnmmires.com/content/1/1/8
Page 5 of 9
Discussion
In this study, we investigated the effect of the metabolic
condition on the biodistribution and uptake rates of FDG
in mice. We found that FDG plasma clearance rates
depend on the dietary state and on insulin stimulation. It
was lowest in fasted animals, probably reflecting a dimin-
ished whole-body glucose disposal rate, as reflected in
the lower Ki for myocardium and skeletal muscle and
possibly related to inhibitory effects of high plasma free
fatty acid concentrations on tissue uptake and a low
membranous expression of GLUT4. The marked increase
in plasma FDG clearance after insulin administration
corresponded to an increase in Ki for myocardium and
skeletal muscle. Because skeletal muscle constitutes a sig-
nificant fraction of the body mass in mice [19], the
observed insulin-induced increase in plasma clearance
rates can be attributed to an increase in skeletal muscle
FDG uptake and, thus, an increase in whole-body glucose
disposal rates.
Importantly, graphical analysis could be performed suc-
cessfully (Figure 4), even though plasma glucose concen-
trations differed between groups and markedly changed
over time. The finding suggests that FDG transmembra-
nous transport and phosphorylation rates remained
constant throughout the study, despite significant
changes in blood glucose levels. Insulin prompted
marked increases in transmembranous glucose transport
and phosphorylation rates, as reflected by Ki. In addition,
progressively declining plasma glucose reduced substrate
competition for FDG transport and phosphorylation,
resulting in an increased FDG uptake rate constant that
probably compensated for any FDG clearance in tissue,
thus creating the apparent irreversible uptake of FDG
(i.e., linearity on the Patlak plot). In contrast, insulin had
no effect on cerebral Ki, most likely due to the absence of
GLUT4 in the brain and insulin-independent cerebral
glucose metabolic rates.
Changes in myocardial SUV due to fasting and insulin
for the most part corresponded to changes in Ki. How-
ever, this does not hold true for the non-fasted controls
and the non-fasted insulin group; here, myocardial Ki
was found to be increased after insulin injection even
though myocardial SUVs were similar in both groups.
This disparity may be related to a shortcoming of the
SUV as a widely employed measure of tissue FDG
uptake. Inherent in the use of SUV is the assumption of
a constant radiotracer input function. However, radio-
tracer input functions markedly differed between study
Figure 4 Results of the graphical analysis. Graphical analysis plots for myocardium, skeletal muscle, and brain in a non-fasted (A) and a non-
fasted, insulin injected (B) mouse. The actual observed data points are compared to the least square regression line.
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groups. In the insulin-treated animals, FDG cleared
more rapidly from plasma so that a decrease in circulat-
ing radiotracer activities was associated with a dispro-
portionately lower myocardial SUV.
Brain MRgluc, estimated only in the non-insulin-treated
mice with relatively stable plasma glucose levels averaged
in a non-fasted state about 3.2 mg/min/100 g, a value very
comparable to that reported by our group in mice with
arterial catheters (2.2 mg/min/100 g) [9]. In the skeletal
muscle, the MRgluc in non-fasted control mice (about 1.1
mg/min/100 g) again was of a similar order of magnitude
as those reported for humans during insulin clamping
(about 4.9 mg/min/100 g) [20]. In the myocardium, the
MRgluc in mice (19.4 and 3.3 mg/min/100 g in non-fasted
and fasted mice, respectively) again were similar to those
in humans (12.4 and 4.3 mg/min/100 g after glucose load-
ing and fasting, respectively) [21].
Reduced heart and skeletal muscle glucose or FDG
metabolism under insulin clamping conditions in
patients with type 2 diabetes and coronary artery disease
(CAD) has been reported [22]. It has also been reported
that there was no difference in myocardial glucose meta-
bolism under glucose loading and under insulin clamping
in patients with CAD [23]. Reduced myocardial FDG
metabolism under fasting, glucose loading, and insulin
clamping in patients with type 2 diabetes without CAD
has been reported [24]. On the other hand, myocardial
glucose metabolism in response to insulin clamping is
not always parallel to that in skeletal muscle and/or
whole-body glucose metabolism. For instance, myocar-
dial glucose metabolism was increased or unchanged
with insulin clamping in patients with essential hyperten-
sion, although skeletal muscle and whole-body glucose
metabolism were significantly reduced with insulin
clamping [25]. Myocardial glucose metabolism was not
reduced in patients with type 2 diabetes and essential
hypertension, even though skeletal muscle and whole-
body glucose metabolism was reduced [26]. In patients
with hypertriglyceridemia without hypertension and dia-
betes, myocardial glucose metabolism was not signifi-
cantly reduced under insulin clamping, but skeletal
muscle and whole-body glucose metabolism was signifi-
cantly reduced [27]. These clinical results and the current
results, which showed different responses to insulin sti-
mulation regarding glucose metabolism between heart
and skeletal muscle, indicate that myocardium and skele-
tal muscle might have different mechanisms for regula-
tion of glucose or FDG uptake in response to insulin-
stimulation or insulin clamping.
Regardless of absolute values of Ki and MRgluc, it is
important to note that dietary changes as well as insulin
administrations exerted responses in mice that are com-
parable to those in humans. Fasting diminished the
whole-body glucose disposal rates and glucose uptake in
myocardium and skeletal muscle. Conversely, insulin
raised whole-body FDG and glucose disposal rates and
increased transmembranous transport of FDG and, by
inference, glucose into myocardium and skeletal muscle.
Some limitations have to be considered when inter-
preting our findings. Firstly, no corrections were made
for spillover of activity between arterial blood and myo-
cardium. Activity spillover from myocardium into the
LV blood pool VOI during the initial bolus passage and
the first 60 s used for determining the input function
was likely to be low as seen on the first-pass time-activ-
ity curves (Figure 5). Blood sampling for determination
of FDG plasma concentrations in the current study
eliminated spillover effects on the late phase of the
arterial input function; the validity of this method has
been shown before [8]. Secondly, it has been reported in
humans, that the lumped constant in the myocardium is
influenced by the insulin levels [28]. However in the
current study, a fixed value of 1.0 was used for all
groups because insulin levels were not available and also
because lumped constants have yet to be determined.
Thirdly, isoflurane anesthesia is known to affect myocar-
dial glucose uptake [29,30] and may have influenced the
results. These limitations are, however, unlikely to
reduce the validity of the inter-group comparison,
because the animals in the four study groups were of
similar body weight and, by inference, had similarly
sized organs and were exposed to the same anesthesia.
Identification of effects of substrate competition on
organ glucose utilization rates would have been useful
but would have required measurements of plasma free
fatty acid and lactate levels. The blood volume of mice
limits the amount of blood that can be taken from the
animals. Blood sampling was minimized to avoid exces-
sive stress and its effect on the metabolic state, as
reported previously [31]. The use of arterialized venous
blood samples for estimating glucose metabolic rates
has been well established in humans [32,33], as well as
in rats and mice [1,8].
Conclusions
In this study, we not only measured organ SUVs, uptake
rate constants, and glucose metabolic rates in intact
mice; we were also able to monitor alterations induced
by dietary changes and insulin administration. When
assessing the effect of insulin on the myocardial glucose
metabolism of non-fasted mice, it is not sufficient to
just calculate the SUV; dynamic imaging with kinetic
modeling is necessary. The observed dietary and insulin-
induced changes in organ metabolic rates, as observed
in the current study, are similar to those reported for
humans.
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